3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
4
Breast
2
Plasma cell
1
Other hematologic neoplasm
1
Myeloid
1
Lymphoid
1
Gynecologic
1
Genitourinary
1
Classical hematology
1
CNS
1
Conditions
Endometrial Neoplasms
19
Ovarian Neoplasms
8
Uterine Cervical Neoplasms
7
Triple Negative Breast Neoplasms
4
Parkinson Disease 4, Autosomal Dominant Lewy Body
4
Neoplasms
4
Stomach Neoplasms
3
Squamous Cell Carcinoma of Head and Neck
3
Colorectal Neoplasms
3
Carcinoma, Transitional Cell
3
Carcinoma, Renal Cell
3
Carcinoma, Ovarian Epithelial
3
Carcinoma, Non-Small-Cell Lung
3
Carcinoma, Hepatocellular
3
Vulvar Neoplasms
2
Thyroid Neoplasms
2
Neoplasm Metastasis
2
Fallopian Tube Neoplasms
2
Advanced Endometrial Cancer
2
Adenocarcinoma
2
Urogenital Neoplasms
1
Urinary Bladder Neoplasms
1
Small Cell Lung Carcinoma
1
Recurrence
1
Pancreatic Neoplasms
1
Ovarian Diseases
1
Ovarian Clear Cell Carcinoma
1
Neoplasms, Glandular and Epithelial
1
Melanoma
1
Liver Neoplasms
1
Interventions
pembrolizumab
27
Cyclophosphamide
14
Gemcitabine
13
fludarabine
11
Carboplatin
10
aldesleukin
9
Trastuzumab
9
Specimen Handling
9
Nivolumab
9
Magnetic Resonance Spectroscopy
8
Biopsy
8
olaparib
7
Cisplatin
7
Paclitaxel
6
palbociclib
5
atezolizumab
5
Taxes
5
Early Intervention, Educational
5
Oxaliplatin
4
Methods
4
Irinotecan
4
Drug Therapy
4
Docetaxel
4
Cetuximab
4
Capecitabine
4
Bevacizumab
4
Albumin-Bound Paclitaxel
4
talazoparib
3
spartalizumab
3
pertuzumab
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Pancreatic Neoplasms
×
lenvatinib
×
Gynecologic
×
Clear all
NCT03797326
2026-05-04
LEAP-005
Merck Sharp & Dohme LLC
Phase 2
Completed
611 enrolled
27 charts